Gefitinib (‘Iressa’, ZD1839) is active against brain metastases in a 77 year old patient

By Roggero Enrico   Giancarla Busi   Antonella Palumbo   Augusto Pedrazzini  

Journal of Neuro-Oncology, Vol. 71, Iss. 3, 2005-02 ,pp. : 277-280

Springer Publishing Company

Access to resources Recommend Favorite

Gefitinib ('Iressa', ZD1839): the patients' experience

By Goss G.  

EJC Supplements, Vol. 1, Iss. 8, 2003-10 ,pp. : 29-33

Elsevier

Access to resources Recommend Favorite

Clinical benefit in NSCLC: the evidence for gefitinib ('Iressa', ZD1839)

By Lynch T.  

EJC Supplements, Vol. 1, Iss. 8, 2003-10 ,pp. : 17-22

Elsevier

Access to resources Recommend Favorite

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)

By Hiscox Stephen   Morgan Liam   Barrow Denise   Dutkowski Carol   Wakeling Alan   Nicholson Robert  

Clinical and Experimental Metastasis, Vol. 21, Iss. 3, 2004-05 ,pp. : 201-212

Springer Publishing Company

Access to resources Recommend Favorite

New hope for patients with non-small-cell lung cancer: gefitinib ('Iressa', ZD1839) and other innovative therapies

By Goss G.  

EJC Supplements, Vol. 1, Iss. 8, 2003-10 ,pp. : 1-1

Elsevier

Access to resources Recommend Favorite